A cancer patient has filed a Taxotere hair loss lawsuit, claiming inadequate product warnings left her uninformed about the risk of permanent hair loss.

According to the Taxotere hair loss lawsuit, plaintiff Diane W. is a resident of the state of North Carolina. She alleges that she underwent chemotherapy using Taxotere from September 2007 through August 2008.

Her Taxotere hair loss lawsuit claims she experienced permanent hair loss, also known as alopecia, following her use of the medication. The Taxotere hair loss lawsuit states that she “experienced hair loss after being administered Taxotere and [her hair] continues to present day to be extremely thin and [have] a bald spot.”

Defendant Sanofi faces the following counts: 1) Strict Products Liability- Failure to Warn; 2) Strict Products Liability for Misrepresentation; 3) Negligence; 4) Negligent Misrepresentation; 5) Fraudulent Misrepresentation; 6) Fraudulent Concealment; 7) Fraud and Deceit; and 8) Breach of Express Warranty.

Taxotere Hair Loss Lawsuit Joins MDL

Diane’s claim is filed as part of a large multidistrict litigation, or MDL, centered on allegations that chemotherapy drug Taxotere causes permanent hair loss, also known as permanent alopecia.

Hundreds of women like Diane have filed Taxotere hair loss lawsuits, claiming that with a more effective warning from Sanofi, they could have avoided adverse effects and complications in permanently losing all of their hair.

Patients who undergo chemotherapy treatment generally expect to lose some hair, but they also expect the lost hair will grow back. Many women who underwent treatment with Taxotere allege they were told their hair would grow back again, only to later suffer from permanent alopecia side effects.

The plaintiffs allege the drug’s manufacturers never warned patients they might never get their hair back. Sanonfi allegedly warned consumers in Europe and Canada of the likelihood of the adverse effect, but the company did not publish a similar warning in the U.S.

Allegations against the Sanofi address that permanent alopecia warnings were not indicated in the U.S. until 2015 – a remarkable 20 years after Taxotere had begun selling on the market.

Recovery from a Taxotere Hair Loss Lawsuit

Women who have suffered unexpected permanent hair loss from their use of Taxotere may be eligible for recovery from Sanofi. Recovery and compensation from the lawsuit may help cover related expenses and help compensate for the suffering incurred.

The Taxotere Hair Loss Lawsuit is Case No. 2:17-cv-08725-KDE-MBN and is part of the Taxotere MDL In re: Taxotere (Docetaxel) Products Liability Litigation, MDL No 2740, in the U.S. District Court for the Eastern District of Louisiana.